- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Daily Derm Times: May 21, 2025
Author(s):
Key Takeaways
- Chronic hand eczema studies emphasize self-reported severity, pain burden, and analgesic use, offering insights into patient management.
- AI, particularly ChatGPT, shows potential in dermatology education, impacting clinical decision-making and training.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Journal Digest: May 21
This review of the latest dermatologic studies includes insights into chronic hand eczema, including self-reported severity, burden of pain and use of analgesics, and more.
AI Shows Promise in Early Medical Education
Explore how AI, particularly ChatGPT, impacts dermatology education, revealing strengths and limitations in clinical decision-making and training.
Azathioprine: A Potential Long-Term Treatment for Alopecia Areata
A 10-year study reveals azathioprine's impressive 93% hair regrowth rate in patients with moderate to severe alopecia, highlighting its long-term efficacy and safety.
Triveni Bio Launches First-in-Human Trial for TRIV-509 in Atopic Dermatitis
Triveni Bio initiates a phase 1 trial for TRIV-509, a promising treatment for atopic dermatitis, targeting key inflammatory pathways.
Combining Topical Products with Anti-Aging Procedure Synergistically Improves the Skin Barrier
A recent study reveals that combining topical anti-aging products with Thermage enhances skin hydration and reduces fine lines for lasting results.
Tralokinumab Eases Joint Pain in Patients with AD
Tralokinumab offers a promising alternative for patients with atopic dermatitis experiencing dupilumab-related arthralgia, achieving skin clearance and symptom relief.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
